ImmuCell Corporation (ICCC) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for ImmuCell Corporation, with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -53.37x | -19.50x | -6.79x | -18.94x | -775.80x | -42.00x |
| P/B Ratio | 2.05x | 1.53x | 1.57x | 1.56x | 1.86x | 1.52x |
| P/S Ratio | 2.01x | 1.59x | 2.24x | 2.54x | 3.16x | 2.80x |
| Profitability | ||||||
| Gross Margin | 41.4% | 30.0% | 25.2% | 41.2% | 45.0% | 44.7% |
| Operating Margin | 6.0% | -6.2% | -32.9% | -12.4% | 1.3% | -9.0% |
| Net Margin | -3.8% | -8.1% | -33.1% | -13.4% | -0.4% | -6.7% |
| EBITDA Margin | 7.7% | 4.0% | -14.3% | 1.9% | 14.0% | 10.7% |
| Liquidity | ||||||
| Current Ratio | 4.26x | 3.41x | 2.73x | 4.56x | 6.42x | 5.50x |
| Quick Ratio | 1.93x | 1.80x | 0.87x | 2.59x | 5.20x | 4.55x |
| Leverage | ||||||
| Debt/Equity | 0.49x | 0.55x | 0.67x | 0.41x | 0.32x | 0.38x |
YoY = year-over-year change. Source: FMP..